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Allogeneic hematopoietic cell transplantation (allo HCT) is the only curative therapy for the myelodysplastic
syndromes (MDS) and myeloproliferative neoplasms (MPN), but treatment toxicity has been a barrier to its
more widespread use. The nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte
globulin (ATG) permits the establishment of donor hematopoiesis necessary for the graft-versus-malignancy
effect and is protective against acute graft-versus-host disease (aGVHD), but it has minimal direct cytotoxicity
against myeloid diseases. We explored the use of TLI-ATG conditioning to treat 61 patients with allo HCT for
MDS (n ¼ 32), therapy-related myeloid neoplasms (n ¼ 15), MPN (n ¼ 9), and chronic myelomonocytic
leukemia (n ¼ 5). The median age of all patients was 63 years (range, 50 to 73). The cumulative incidence of
aGVHD grades II to IV was 14% (95% conﬁdence interval [CI], 4% to 23%) and for grades III to IV, 4% (95% CI, 0 to
9%), and it did not differ between patients who received allografts from related or unrelated donors. The
cumulative incidence of nonrelapse mortality (NRM) at 100 days, 12 months, and 36 months was 0%, 7%, and
11%. Overall survival and progression-free survival were 41% (95% CI, 29% to 53%) and 35% (95% CI, 23% to
48%), respectively. The safety and tolerability of TLI-ATG, as exempliﬁed by its low NRM, provides a foun-
dation for further risk-adapted or prophylactic interventions to prevent disease progression.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION determination of early versus deferred allo HCT. In the
Allogeneic hematopoietic cell transplantation (allo HCT)
is the only curative therapy for the myelodysplastic
syndromes (MDS) and the myeloproliferative neoplasms
(MPN). MDS and, to a lesser extent MPN, affects older pa-
tients who are often deemed ineligible for myeloablative
preparative regimens because of the regimen-related
toxicity. Increasingly, MDS and MPN patients are offered
reduced-intensity conditioning (RIC) with the goal of shifting
the burden of disease control from the preparative regimen
to the donor immune system. Nonetheless, allo HCT carries
intrinsic risk of therapy-related mortality that limits its more
widespread use.
The optimal timing of allo HCT in MDS and MPN is difﬁ-
cult to discern, as the risk of disease progression is highly
variable. Recently, therapies for MDS, such as DNA methyl-
transferase inhibitors (DNMTi), have been shown to alter the
natural course of the disease in 40% to 50% of high-risk pa-
tients, yet responses are often incomplete and rarely durable
[1,2]. Prognostic scoring systems have been valuable for thedgments on page 842.
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14.02.023absence of randomized controlled trials, decision analytic
tools have suggested that for patients with an HLA-matched
sibling donor, early myeloablative allo HCT prolongs life ex-
pectancy for eligible patients with International Prognostic
Scoring System (IPSS) intermediate 2e (Int-2) and high-risk
disease, but it shortens life expectancy for patients with low-
or intermediate 1e (Int-1) risk disease [3]. Similar statistical
techniques were applied to analyze patients older than 60
years [4]. Again, early transplantation maximized life ex-
pectancy only for patients with IPSS Int-2 and high-risk
disease. However, the generalizability of these conclusions
is limited by the variety of conditioning regimens available to
older patients. Treatment-related mortality among MDS
patients receiving RIC-based transplants has historically
ranged from 25% to 40% [5-7].
We and, more recently, others have reported the out-
comes of patients treated with a nonmyeloablative regimen
of total lymphoid irradiation (TLI) and antithymocyte glob-
ulin (ATG) for the treatment of myeloid and lymphoid ma-
lignancies [8-11]. This regimen has minimal, if any, direct
cytotoxic effects towards myeloid neoplasms. Rather, it is
primarily immune modulatory, resulting in the enrichment
of regulatory lymphocytes in the recipient [8,12]. As a
consequence, allo HCT after TLI-ATG depends on an effective
graft-versus-malignancy (GVM) response for control of dis-
ease. The objectives of the current study were to determineTransplantation.
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free survival (RFS) for patients with MDS and MPN
receiving allogeneic HCT after TLI-ATG conditioning.
MATERIALS AND METHODS
Patients and Donors
The study group included 61 consecutive patients with MDS/MPN
treated between August 1, 2004 and December 31, 2011 on a trial of non-
myeloablative conditioning with allogeneic transplantation. All patients
provided written informed consent and were treated at Stanford University
Medical Center. The protocol and informed consent documents were
approved by the institutional review board of Stanford University in
accordance with the Declaration of Helsinki (http://clinicaltrials.gov
NCT00185796). The censoring date was the last clinic visit before July 1,
2012, allowing for a minimal follow-up of 18 months.
Patients from 50 to 75 years old were eligible. Exclusion criteria were
creatinine clearance of <60 mL/min or serum creatinine > 2 mg/dL, left
ventricular ejection fraction < 30% or uncontrolled congestive heart failure,
diffusing capacity of the lungs for carbon monoxide < 40% predicted, liver
dysfunction as indicated by total bilirubin > 3 mg/dL, or aspartate amino-
transferase or alanine aminotransferase > 4 times the upper limits of
normal, Karnofsky performance status < 60%, active central nervous system
involvement with disease, and treatment-refractory fungal or bacterial
infections.
Eligible diagnoses included MDS (including the FAB subtypes refractory
anemia, refractory anemia with excess blasts, refractory anemia with ring
sideroblasts, or chronic myelomonocytic leukemia [CMML]), therapy-
related myeloid neoplasms (t-MN), or advanced MPN excluding Philadel-
phia chromosomeepositive chronic myelogenous leukemia. Patients with
polycythemia vera or essential thrombocythemia were eligible if they had
progressed to a ﬁbrotic stage or experienced persistent complications
(eg, hemorrhage or thrombosis) despite conventional therapy. Patients with
marrow blast percentage of greater than or equal to 10% required cytor-
eduction before the preparative regimen to achieve a marrow blast per-
centage of less than 10%. Patients with prior acute myelogenous leukemia
(AML) required cytoreduction to achieve a marrow blast percentage of less
than 5%. Cytoreductive regimenswere chosen and administered by referring
physicians.
Patients with de novo MDS were assigned to a revised IPSS (IPSS-R) risk
group from laboratory features at diagnosis and within 30 days before allo
HCT [13]. Patients with t-MN, CMML, and MPN were not assigned IPSS-R
scores. Status at transplantation was assessed by bone marrow evaluation
with conventional metaphase cytogenetics. The hematopoietic cell trans-
plantation comorbidity index (HCT-CI) score was assigned according to
clinical features and history at the time of allo HCT [14]. All donor-recipient
pairs were HLA matched or single antigen/allele mismatched after high
resolution typing for HLA-A, B, C, DRB1, and DQB1.
Treatment and Evaluations
The preparative regimen consisted of TLI with a cumulative dose of
12 Gy in 10 fractions as previously described [10]. Rabbit ATG (Thymoglo-
bulin, Genzyme or Sanoﬁ) was administered day -11 to day -7 in doses of
1.5 mg/kg for a total dose of 7.5 mg/kg. Unmanipulated granulocyte-colony
stimulating factoremobilized peripheral blood mononuclear cells were
infused on day 0. GVHD prophylaxis consisted of cyclosporine A (CsA) and
mycophenolate mofetil (MMF). CsA began day -3 at a dose of 5 mg/kg orally
twice daily with a target trough level of 350 to 450 ng/mL. Oral MMF
administration began on day 0 after HCT at a dose of 15 mg/kg. Patients who
received related donor grafts received MMF twice daily and those who
received unrelated donor grafts received MMF 3 times daily.
Immune-suppressant medication was tapered in the absence of GVHD
as follows: MMFwas discontinued for patients with matched related donors
on day 28. For patients with unrelated donors, MMF was tapered by
approximately 10% weekly beginning on day 40 with the taper completing
by day 96. The CsA taper commenced for patients with matched related
donors on day 56 and after completion of the MMF taper for patients with
unrelated donors.
Anti-infective prophylaxis and treatment were administered per insti-
tutional standards. Patients at risk for cytomegalovirus (CMV) reactivation
were screened with quantitative PCR of peripheral blood weekly beginning
on day -11 until day 100. Pre-emptive therapy for CMV viremia was insti-
tuted per institutional guidelines. All patients were screened for Epstein-
Barr virus viremia by quantitative PCR every other week.
Chimerism, Lymphocyte Subset Analysis, and Response Assessments
Donor cell chimerism analysis was determined by quantitative PCR of
polymorphic short tandem repeats from unfractionated peripheral bloodleukocytes and immunomagnetically puriﬁed CD3þ, CD15þ, CD19þ, and
CD56þ cells [15]. These tests were performed monthly for the ﬁrst 3 months
after allo HCT and then annually or more frequently at the discretion of the
treating physician. Engraftment was characterized per standard criteria [16].
Speciﬁcally, primary graft failure was deﬁned as failure to achieve greater
than 5% donor CD3þ cells at any time point. Secondary graft failure was
deﬁned as donor CD3þ cells less than 5% after prior chimerism of greater
than 5%. Mixed chimerism was deﬁned as between 5% and 95% peripheral
blood donor CD3þ cells. Full chimerism was deﬁned as greater than 95%
donor CD3þ. Flow cytometry of peripheral blood mononuclear cells was
performed monthly for the ﬁrst 3 months after allo HCT, as previously
described [10].
Bone marrow aspirates and biopsies were obtained at 3, 6, and 12
months and yearly until year 5 after transplantation. Disease relapse was
deﬁned as recurrence or progression of morphologic abnormalities and/or
by recurrence or persistence of a previously identiﬁed cytogenetic abnor-
mality. All occurrences of acute or chronic GVHD (cGVHD) were graded
according to established criteria [17,18]. Corticosteroids were added for
patients with grade II to IV aGVHD at the discretion of the treating physician.
Treatment of relapse or progression was administered by the referring he-
matologist with or without donor lymphocyte infusions (DLI). Relapse, but
not isolated low chimerism, was the only indication for DLI.
Statistical Analysis
Overall survival (OS) was deﬁned as time from transplantation to death
from any cause. RFS was deﬁned as time from transplantation to relapse,
progression, or death from nonrelapse causes. Living patients without
progression/relapse were censored at the date of last contact. Univariate
survival probabilities were generated by the product-limit method [19]. The
cumulative incidence estimates for aGVHD, cGVHD, and NRM were calcu-
latedwith relapse and graft failure as competing risks [20]. The log-rank test
was used to compare univariate survival probabilities. Univariate analysis of
risk factors for all outcomes was performed using Cox regression. Approx-
imate 95% conﬁdence intervals (CIs) are provided for point estimates of OS,
RFS, relapse incidence, GVHD incidence, and NRM. The relationship between
donor-host chimerism and relapse probability was analyzed by generation
of receiver operating characteristic (ROC) curves.
RESULTS
Patient Characteristics
Pretransplantation characteristics for all patients are
indicated in Table 1. To summarize, 61 patients underwent
allo HCT from August 2004 through December 2011, inclu-
sive. The median age was 63 years and 26% had an HCT-CI
score of 3 or greater. De novo MDS was the most frequent
diagnosis (52%), followed by therapy-related MDS (24%),
MPN (15%), and CMML (8%). Thirty-ﬁve percent of patients
had been diagnosed with AML at some point in their disease
course before allo HCT. All but 9% of patients received
chemotherapy before allo HCT, including AML-type induc-
tion chemotherapy, DNMTi such as 5-azacytidine or deci-
tabine, or immunomodulatory agents, such as lenalidomide
or thalidomide. IPSS-R scores at diagnosis were assessed for
the 32 patients with de novoMDS. Fourteen had high or very
high risk, 7 had intermediate, and 11 were good or very good
risk. Of this last group of good- and very gooderisk patients,
before transplantation, 3 had progressed to AML, 1 to re-
fractory anemia with excess blasts-2, and 5 were transfusion
dependent. At the time of transplantation, 14% of patients
had 5% or more bone marrow blasts, and 38% had persistent
cytogenetic abnormalities. According to the IPSS-R criteria,
4 patients had features consistent with high- and very
higherisk disease, 10 met criteria for intermediate-risk
disease, and the remaining 18 were characterized as hav-
ing good- or very gooderisk status. Donor types were
matched related (41%), matched unrelated (44%), and mis-
matched unrelated (15%). All patients received granulocyte-
colony stimulating factoremobilized peripheral blood
grafts. The median CD34þ cell dose was 6.1 106/kg (range,
.6 to 16.5) and the median CD3þ cell dose was 3.2  108/kg
(range, 1.4 to 6.3).
Figure 1. Kaplan Meier estimates of (A) overall survival (OS) and relapse-free
survival (RFS) for all patients, (B) RFS and (C) nonrelapse mortality (NRM)
stratiﬁed according to donor.
Table 1
Patient Characteristics
Characteristic Value (range)
Male 39 (64)
Female 22 (36)
Age at transplantation, median, yr 63 (50-73)
Time from diagnosis to HCT, median, mo 11 (3-160)
HCT-comorbidity index
0 26 (43)
1-2 19 (31)
3 16 (26)
Diagnosis
De novo MDS 32 (52)
t-MN 15 (24)
MPN 9 (15)
CMML 5 (8)
Ever AML
Yes 18 (35)
Prior therapy, n (%)
Cytotoxic only 16 (26)
DNMTi and/or IMID 28 (46)
Cytotoxic þDNMTI/IMID 8 (13)
None/supportive care 9 (15)
Blast percentage at transplantation
5 54 (86)
>5 7 (14)
Abnormal BM cytogenetics at transplantation
Yes 23 (38)
No 32 (52)
Unknown/indeterminate 6 (10)
Donor
Matched related 25 (41)
Matched unrelated 27 (44)
Mismatched unrelated 9 (15)
MDS indicates myelodysplasia; t-MN, therapy-related myeloid neoplasm;
MPN, myeloproliferative neoplasm; CMML, chronic myelomonocytic leu-
kemia; DNMTI, DNAmethyltransferase inhibitor; IMID, immunomodulatory
drug; BM, bone marrow; AML, acute myelogenous leukemia; HCT, he-
matopoietic cell transplantation.
Data presented are n (%) unless otherwise indicated.
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The preparative regimen of TLI-ATG included a planned
5-day hospitalization for administration of ATG but was
otherwise designed for the outpatient setting. Fifty-nine of
61 patients (97%) received donor cell infusions as out-
patients. Twenty-nine (48%) patients were admitted to the
hospital before day 100 after transplantation and the me-
dian duration of hospitalization was 5 days (range, 1 to 114.)
The most frequent indication for admission was fever
(n ¼ 12), including 7 patients with febrile neutropenia. Four
patients were readmitted for management of nausea or
abdominal pain. Fifty patients (82%) were at risk for CMV
and 20 patients reactivated CMV within the ﬁrst 100 days,
with a median time to reactivation of 45 days (range, 17 to
88). Two patients developed CMV disease (enteritis and
pneumonitis) and both cases were treated to resolution
with antiviral medications. Seven patients demonstrated
asymptomatic Epstein-Barr virus reactivation and none
required therapy.
Engraftment
All patients underwent evaluation of donor chimerism.
Three patients (5%) had primary graft failure, as indicated by
failure to achieve donor CD3 chimerism of greater than 5%.
Each of these patients had marrow hypercellularity at the
initiation of the conditioning regimen, and 1 had 8% myeloid
blasts. Thirty patients achieved full CD3 chimerism with a
median time of 90 days (range, 28 to 730). Thirty-seven pa-
tients achieved full CD15 chimerism with a median time of56 days (range, 28 to 730). Five patients, 2 with MDS, and 3
with MPN, experienced secondary graft failure and 4 have
been diagnosed with overt relapse. One patient with sec-
ondary graft rejection remains alive without evidence of
disease. Secondary graft rejection was observed as early as
2 months and as late as 1 year after transplantation. T cell
reconstitution was evaluable at day 28 in 49 of 61 patients.
Themedian CD3 count was 199/mm3 (range,12 to 1268). The
median donor CD3 count was 141/mm3 (range, 2 to 986) and
recipient, 43/mm3 (range, 1 to 560).Survival
Thirty-six month OS and RFS were 41% (95% CI, 29% to
53%) and 35% (95% CI, 23% to 48%), respectively (Figure 1A).
Donor source did not appear to signiﬁcantly impact overall
outcomes (Figure 1B). NRM at 100 days, 12 months, and 36
months was 0, 7, and 11%, respectively (Figure 1C). Causes of
NRMwere cGVHD (n¼ 3), infections (n¼ 2), and liver failure
not attributable to GVHD (n ¼ 1). The 36-month cumulative
incidence of relapse was 61% (95% CI, 47% to 74%). The me-
dian time to relapsewas 5.6 months (range, .4 to 36.5). Of the
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quent therapy, including 2 patients who received unfractio-
nated DLI and 1 who received allogeneic cytokine-induced
killer cells [21]. Five patients with relapse remain alive, with
a median time from relapse to censoring date of 26 months
(range, 16 to 31).
GVHD
The cumulative incidence of aGVHD (grade II to IV) was
14% (95% CI, 4% to 23%) and grade III and IV was 4% (95% CI,
0 to 9%). Themedian time to the onset of aGVHDwas 51 days.
There was no difference in aGVHD according to donor type
(P ¼ .25). No patients died from aGVHD. The cumulative
incidence of cGVHD was 33% (95% CI, 20% to 47%) with me-
dian time to onset of 199 days (range, 112 to 475). There was
no signiﬁcant difference in the incidence of cGVHD according
to donor status (P ¼ .52). Of the patients with cGVHD, 71%
had no prior history of aGVHD.
Univariate Analysis of Factors for Association with
Outcome
The 36-month RFS was not signiﬁcantly different for
patients with MDS, MPN, t-MN, or CMML (data not shown).
Univariate analysis of pretransplantation characteristics
failed to reveal a signiﬁcant association between relapse and
blast percentage in the bone marrow >5% at transplantation
(P ¼ .67) or the presence of abnormal cytogenetics at trans-
plantation (P ¼ .54). There was no difference in OS, RFS,
relapse, or treatment-related mortality for patients with
related versus unrelated donors. IPSS-R was calculated for
features present at diagnosis and at transplantation among
the patients with de novo MDS. Patients with good and very
good IPSS-R scores at diagnosis had a 36-month cumulative
incidence of relapse of 43%, which was not signiﬁcantly
different from that of patients with intermediate-risk disease
(Figure 2A). Those patients with high and very higherisk
disease at diagnosis had a relapse risk of 78% (P ¼ .04).
Reassessment at the time of allogeneic transplantation
was also performed and showed that patients with high andFigure 2. Relapse proportion according to IPSS-R (A) at diagnosis or (B) at the
time of allo HCT.very higherisk disease all succumbed to early relapse
(Figure 2B). Outcomes among patients with HCT-CI scores of
3 tended to have worse outcomes, although this did not
reach statistical signiﬁcance (data not shown).
Chimerism and Relapse Risk
To analyze early determinants of relapse, we performed
ROC analysis of donor chimerism at days 28 and 56 after
transplantation. CD15þ cell chimerism (a continuous random
variable) at day 28 provided the best discrimination of no
relapse (true positives) versus relapse (false positive). The
median day 28 CD15þ cell chimerism was 72% (range, 0 to
99%) versus 90% (range, 29% to 100%) among patients who
did and did not relapse, respectively (Figure 3A). Establishing
a cutoff of 90% provided 77% sensitivity and 61% speciﬁcity
for relapse. Patients who achieved donor CD15þ of 90% at
day 28 had a 2-fold relative risk (95% CI, 1.05 to 3.94) of
achieving full CD3þ cell chimerism. Patients with day
28 CD15þcell chimerism of 90% had signiﬁcantly lower risk
of relapse (hazard ratio, .38, 95% CI, .20 to .72) (Figure 3B). By
contrast, the median day 28 CD3þ cell chimerism was 70%
(range, 0 to 98%) versus 80% (range, 25% to 98%) among
patients who did and did not relapse (Figure 3C). Patients
with day 28 CD3þ chimerism of 90% also had reduced risk
of relapse (hazard ratio, .49, 95% CI, .25 to .98) (Figure 3D).
DISCUSSION
This study demonstrates that for patients with MDS and
MPN, nonmyeloablative conditioning with TLI-ATG is asso-
ciated with a low incidence of transplantation-related com-
plications and mortality. Our study included only patients
50 years old or older, a cohort for whom, until recently, had
few therapeutic options other than supportive care. Thirty-
ﬁve percent of patients had prior evolution to AML, and
26% had an HCT-CI of 3 or greater. Most patients did not
require hospital admission after allo HCT. NRM at 100 days
was 0%. The estimated 36-month RFS and OS were 35% and
41%, comparable to that reported by for myeloablative or RIC
conditioning using other more aggressive regimens [22].
The low incidence of NRM reported here (8%) is due in
part to the infrequent occurrence of aGVHD (II to IV) (14%)
after TLI-ATG. In most studies of MDS and MPN, for patients
treated on RIC regimens, the risk of aGVHD is comparable to
that observed for patients treated with myeloablative regi-
mens. Laport et al. reported the outcome of a multicenter
trial with a preparative regimen of low-dose total body
irradiation with or without ﬂudarabine [23]. The rate of
aGVHD (II to IV) was 38%, 3-year NRM was 32%, and OS was
27%. Nakamura et al. reported that a RIC regimen of ﬂudar-
abine and melphalan, followed by GVHD prophylaxis with
sirolimus and tacrolimus, was associated with a 35% rate of
aGVHD (grades II to IV), and approximately 70% risk of
cGVHD, although NRM was only 10.5% at 2 years. At 2 years,
only 21% of patients experienced relapse, resulting in OS of
75% [24]. Potter et al. described the single-center experience
ﬂudarabine, busulfan, and alemtuzumab conditioning for
patients with MDS. AGVHD (II to IV) and cGVHD were 20%
and 19% with 5-year NRM of 26%, relapse of 51%, and OS of
44% [25].
Registry data provides comparable rates of aGVHD to the
Laport and Nakamura studies. In a retrospective analysis of
the Center for International Blood and Marrow Transplant
Research data of MDS patients receiving various RIC regimens
for transplantation, the incidence of aGVHD grades II to IVwas
31%, NRM at 1 year was 29% to 35%, and OS was 34% [5]. In a
Figure 3. (A,C) Day 28 CD15þ or CD3þ cell donor chimerism among patients according to relapse. (B,D) Cumulative incidence of relapse among patients stratiﬁed
according to day 28 CD15þ or CD3þ cell chimerism.
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Marrow Transplantation registry, NRM was 32% and OS was
32% after RIC conditioning, with 40% of patients experiencing
relapse and 32% with NRM. By comparison, patients under-
going myeloablative conditioning had NRM of 44% and OS
30%. Luger et al., in a review of the Center for International
Blood and Marrow Transplant Research registry, reported OS
of 34% for patients receiving myeloablative conditioning
or RIC conditioning, but 26% for those receiving non-
myeloablative conditioning [26-28]. Therefore, the results
achieved with TLI-ATG are comparable in overall outcome;
however, they are associated with lower NRM and acute
GVHD.
ATG has the potential to deplete aGVHD-causing donor T
cells, and randomized trial data have demonstrated that ATG
decreases aGVHD after myeloablative conditioning [29,30].
No randomized trial of ATG after RIC has been reported.
Analysis of registry data has failed to show decreased inci-
dence of aGVHD with pretransplantation ATG when
compared with T cellereplete regimens [31]. Because RIC
regimens rely on the GVM effect mediated primarily by
donor T cells, the potential impact of ATG on relapse remains
an area of great interest. We do not believe that ATG,
administered on days -11 to -8 in this regimen, has a direct
impact on donor T cells, because active ATG, ie, capable of
binding CD3þ T cells, is nearly undetectable in serum on the
day of transplantation [10].
The low incidence of aGVHD reported here may be
attributable to the enrichment of regulatory lymphocytes, as
has been shown in preclinical murine models [32]. It is also
possible that the low incidence of aGVHD is attributable to
delayed achievement of full donor CD3þ chimerism, as it is
generally believed that full donor CD3þ chimerism is
necessary for the development of GVHD [33]. Interestingly,
achievement of full donor chimerism among patients with
MDS and MPN receiving TLI-ATG is not as prevalent as
those with AML and non-Hodgkin lymphoma [8], yet theincidences of aGVHD among these different populations are
comparable. It has been observed previously that achieve-
ment of full donor chimerism is less frequent among patients
with MDS compared with those with other hematologic
malignancies [34]. It is unclear whether this is due to the
intensity, or lack thereof, of previous myelosuppressive or
immunosuppressive chemotherapy, or whether it reﬂects a
property of the underlying disease and the bone marrow
stroma.
Despite the low incidence of aGVHD, cGVHD was
observed in one third of patients, most of whom had no prior
history of aGVHD. Although it is widely accepted that a his-
tory of aGVHD is the strongest predictor for the development
of cGVHD [35], there are precedents of alternative GVHD
prophylaxis resulting in much lower rates of aGVHD than
cGVHD [36,37].
For both myeloablative and RIC, decision analysis has
suggested that the beneﬁt of frontline allo HCT outweighed
the risk of treatment-related toxicity for those with Int-2 or
high-risk disease. In contrast, patients in IPSS low or Int-1
risk groups may have shortened survival when treated
with up front allo HCT [3]. Among low and Int-1 patients, allo
HCT was best deferred until disease progression. Nonethe-
less, the overall tolerability of the TLI-ATG regimen and the
low NRM suggest that allo HCT may afford survival beneﬁt
compared with conventional therapies when offered to
patients with lower risk disease earlier in their treatment
course.
Nonetheless, the majority of patients in the current study
either presented with high-risk disease or had evidence of
disease progression before transplantation, including
35% who had progressed to AML. Patients with low-risk
disease by IPSS or IPSS-R criteria and who had not pro-
gressed were mostly red blood cell transfusion dependent, a
high-risk feature according to the World Health Organiza-
tion Prognostic Scoring System [38]. The vast majority had
received therapy with DNMTi, immunomodulatory, or
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staged” by prior therapy so that few patients had more than
5% marrow blasts at the time of transplantation. Despite
favorable responses to prior therapy, it was anticipated that
without additional therapy, their disease would soon prog-
ress. For instance, of the 40% of patients whomay respond to
azacytidine, the median duration of response is only 8 to 10
months [39] and the median survival for high- and low-risk
patients after azacytidine failure is only 5.6 and 17 months,
respectively [40]. Likewise, for patients receiving decitabine,
the median duration of response is 9 months. Survival after
decitabine treatment failure is approximately 4 months [41].
There is no standard treatment after DNMTi treatment fail-
ure. Among patients with azacytidine treatment failure, allo
HCT afforded median OS of 19 months, signiﬁcantly longer
than that seen with intensive chemotherapy, low-dose
chemotherapy, or best supportive care [42]. Of course, the
ability to proceed to allo HCT is limited to patients with an
adequate performance status, available donors, and some
measure of disease control.
As with other RIC regimens for patients with MDS/MPN,
disease relapse remains the most vexing problem after
TLI-ATGebased conditioning and suggests that post-
transplantation prophylaxis or risk-adapted therapy are
warranted. We sought to understand the impact of disease
characteristics at diagnosis and disease burden at trans-
plantation on outcome. Univariate analysis of factors, such as
cytogenetic abnormalities or blast percentage, failed to
reveal a signiﬁcant association with relapse or survival, but
the small number of patients with these abnormalities may
not have provided adequate statistical power to detect an
association. We found that a composite measure, the IPSS-R,
as assessed immediately before allo HCT, was associatedwith
relapse. As with the IPSS, the IPSS-R was derived to assign
prognosis from features present at diagnosis and is not a
dynamic scoring system. It is not to be inferred that the
IPSS-R immediately before transplantation confers equiva-
lent prognostic information as the IPSS-R as assessed at
diagnosis, but, rather, it is a marker of disease burden. Of
note, among patients with IPSS-R high- or very higherisk
scores at the time of diagnosis, approximately 20% experi-
enced long-term disease-free survival. However, all patients
with high- or very higherisk scores at the time of allo HCT
had early relapse or death. We conclude from this observa-
tion that patients with a high IPSS-R at transplantation
require either additional therapy before TLI-ATG or more
aggressive transplantation conditioning regimens.
To further identify patients with a high risk of relapse, we
studied earlier chimerism. Using ROC analysis, we found that
day 28 CD15þ cell donorespeciﬁc chimerism provided the
best discrimination of no relapse versus relapse. In our
analysis, failure to achieve 90% donor CD15þ chimerism by
day 28 was 77% sensitive and 61% speciﬁc for relapse. It is
generally held that achievement of full donor CD3þ cell
chimerism is associated with GVM effects. It is conceivable
that persistent recipient CD15þ cells represent residual
malignancy, although this is unclear, as immunophenotype
of the malignant clone was not always available.
Most of the patients who relapse after allo HCT retained a
performance status that allowed for additional post-
transplantation therapy, including DLI. Although most
patients who relapse ultimately succumbed to their disease,
5 patients demonstrated achieved durable remissions with
post-transplantation therapy. The low incidence of early
NRM and the overall tolerability of TLI-ATG support thefeasibility of post-transplantation intervention for patients
with markers of impending relapse.
In summary, our results demonstrate that allo HCT after
TLI-ATG conditioning can result in long-term RFS with low
risk of aGVHD and NRM for elderly patients with MDS and
CMML utilizing either matched related or unrelated donors,
primarily because of a low incidence of treatment-related
complications. Because of the low incidence of treatment-
related complications, allogeneic HCT with TLI-ATG condi-
tioning could be utilized with relative safety earlier in the
course of disease and may alter treatment algorithms.
Relapse is the predominant cause of treatment failure,
especially in patients with more advanced disease. After allo
HCT, a risk-adapted approach may be based on early
chimerism results.ACKNOWLEDGMENTS
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